Tobacco in the tabloids: How the Weekly World News covered smoking for laughs—and the National Enquirer wouldn’t cover it at all

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

“Trick Cigar Blows Man’s Head Off”

In a new online exhibition, The University of Alabama Center for the Study of Tobacco and Society examines tobacco in the tabloids. 

This exhibition is drawn from the Center’s collection of supermarket tabloid newspapers with stories about smoking in the 40 years following the publication in 1964 of the Surgeon General’s Report on Smoking and Health—when the few early anti-smoking messages by the American Cancer Society and other health organizations were being drowned out by the torrent of cigarette ads on TV (until 1971), on billboards, at sports events, and in newspapers and magazines. 

Tabloid headline reads: "Cigarette Company Targets Babies".
Tabloid headline reads: "Militant anti-smoking group blamed after… TRICK CIGAR BLOWS MAN’S HEAD OFF! ‘He took two puffs and then –BOOM!’ says restaurant manager”.
Tabloid headline reads: "Owners forced to buy cigarettes for pooches addicted to smoking. Dogs born with intense cravings for nicotine, say stunned vets."
Tabloid headline reads: "New York mom of 6-year-old does slow burn. 'If my daughter can't smoke in school - I'll sue'"
Tabloid headline reads: "Cigarettes cured my cancer"
Tabloid headline reads: "Discovered at last: Cancer-proof cigarettes!"

Because of the tabloids’ large circulation and their readers’ lower educational attainment compared to the major newsweeklies TIME, Newsweek, and U.S. News & World Report — which were heavily dependent on cigarette advertising and minimized their coverage of smoking and cancer — these publications could have played a life-saving role in educating the public about the devastating health consequences of cigarette smoking. 

Instead, they, too, passed the buck.

Read more on the Cancer History Project

Related articles by the Center for the Study of Tobacco and Society


This column features the latest posts to the Cancer History Project by our growing list of contributors

The Cancer History Project is a free, web-based, collaborative resource intended to mark the 50th anniversary of the National Cancer Act and designed to continue in perpetuity. The objective is to assemble a robust collection of historical documents and make them freely available.  

Access to the Cancer History Project is open to the public at CancerHistoryProject.com. You can also follow us on Twitter at @CancerHistProj, or follow our podcast.

Is your institution a contributor to the Cancer History Project? Eligible institutions include cancer centers, advocacy groups, professional societies, pharmaceutical companies, and key organizations in oncology. 

To apply to become a contributor, please contact admin@cancerhistoryproject.com.

Table of Contents

YOU MAY BE INTERESTED IN

Lauren Averett Byers, professor of thoracic/head & neck medical oncology at the University of Texas MD Anderson Cancer Center, received the 2025 Edith and Peter O’Donnell Award in Medicine from the Texas Academy of Medicine, Engineering, Science and Technology. The award recognizes her fundamental discoveries and contributions to identifying novel therapeutic strategies for small cell lung cancer, which have paved the way for personalized treatments, even in the most highly recalcitrant cancers.
Break Through Cancer has launched the PoweRD 2 Cure ALK+ Lung Cancer TeamLab, a collaboration among nine leading cancer research institutions, including Break Through Cancer’s five partner institutions: Dana-Farber Cancer Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Memorial Sloan Kettering Cancer Center, MIT’s Koch Institute for Integrative Cancer Research, and the University of Texas MD Anderson Cancer Center, as well as newly engaged collaborators from Mass General Brigham, Boston Children’s Hospital, the University of Colorado Cancer Center and Vanderbilt University Medical Center.
Genentech’s phase III SKYSCRAPER-01 study, evaluating tiragolumab combined with Tecentriq (atezolizumab) compared to Tecentriq alone for patients with PD-L1-high, locally advanced or metastatic non-small cell lung cancer, did not reach the primary endpoint of overall survival at the final analysis. The overall safety profile observed remained consistent with longer follow-up, and no new safety signals were identified. The detailed data will be presented at a medical meeting in 2025.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login